Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells-Reference-Cited by-同舟云学术

Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells

Published:2024-07-24 Issue:1 Volume:15 Page:
ISSN:2730-6011
Container-title:Discover Oncology
language:en
Short-container-title:Discov Onc

Author:

Wenyao Chen,Shuai Ma,Yifeng Fan,Xinzhi Li,Xiangyong Que

Abstract

Abstract Purpose This study aims to investigate the effect of Niraparib in combination with an Anti-GD2 Antibody on osteosarcoma cells. Methods Scratch test was utilized to assess cell migration capacity, while the Transwell experiment was utilized to evaluate cell invasion potential. Cell proliferation was measured using the CCK8 experiment. The affinity between the anti-GD2 antibody and its antigen was determined via ELISA. Tumor growth was evaluated through animal experiments. Western blotting, QRT-PCR, and histological analysis were conducted to examine the expression of relevant proteins and mRNAs. Results MG63 cell line was used for an example. The scratch test showed that the migration rate of osteosarcoma cells in Niraparib + Anti-GD2 group was 1.07 ± 0.04 after 48 h, and 0.34 ± 0.04 in the Control group. Transwell experiment showed that the invasion ability of osteosarcoma cells in Niraparib + Anti-GD2 group was 21.0 ± 1.5, and that in Control group was 87.7 ± 2.9. CCK8 experiment showed that the absorbance value of Niraparib + Anti-GD2 group was 0.16 ± 0.10 on day 5, and that of the Control group was 0.76 ± 0.09. Western blotting showed that the expression levels of BALP and CICP in Niraparib + Anti-GD2 group were 0.751 ± 0.135 and 1.086 ± 0.115, respectively, and those in Control group were 1.025 ± 0.143 and 1.216 ± 0.168, respectively. QRT-PCR results showed that the absorbance values of Niraparib + Anti-GD2 group were 0.173 ± 0.065 and 0.170 ± 0.078 on day 14. The results of animal experiments showed that on day 5, the tumor volume of the Control group was 2433 ± 391, and that of the Niraparib + Anti-GD2 group was 1137 ± 148. Histological analysis showed that the mean density values of Niraparib + Anti-GD2 group were 0.19 ± 0.08 and 0.22 ± 0.07, and those of Control group were 0.26 ± 0.09 and 0.29 ± 0.10. Conclusion The combination of Niraparib and Anti-GD2 antibody significantly inhibits Osteosarcoma cells.

Funder

Natural Science Foundation of Hubei Province

China Three Gorges University basic and clinical pathology research center foundation

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12672-024-01166-y.pdf

Reference40 articles.

1. Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y, Qian A. Bone microenvironment and osteosarcoma metastasis. Int J Mol Sci. 2020;21(19):6985. https://doi.org/10.3390/ijms21196985.PMID:32977425;PMCID:PMC7582690.

2. Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18(10):609–24. https://doi.org/10.1038/s41571-021-00519-8.

3. Ramos L, Truong S, Zhai B, Joshi J, Ghaidi F, Lizardo MM, Shyp T, Kung SHY, Rezakhanlou AM, Oo HZ, Adomat H, Le Bihan S, Collins C, Bacha J, Brown D, Langlands J, Shen W, Lallous N, Sorensen PH, Daugaard M. A bifunctional PARP-HDAC inhibitor with activity in ewing sarcoma. Clin Cancer Res. 2023;29(17):3541–53. https://doi.org/10.1158/1078-0432.CCR-22-3897.

4. Dong M, Luo H, Liu R, Zhang J, Yang Z, Wang D, Wang Y, Chen J, Ou Y, Zhang Q, Wang X. Radiosensitization of osteosarcoma cells using the PARP inhibitor olaparib combined with X-rays or carbon ions. J Cancer. 2024;15(3):699–713. https://doi.org/10.7150/jca.90371.

5. Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;1(500):1–10. https://doi.org/10.1016/j.canlet.2020.12.024.